Pluri Inc. (NASDAQ:PLUR) Short Interest Up 70.5% in August

Pluri Inc. (NASDAQ:PLUR) saw a large growth in short interest in the month of August. As of August 31st, there was short interest totaling 26,450 shares, a growth of 70.5% from the August 15th total of 15,514 shares. Currently, 0.4% of the company’s shares are short sold. Based on an average daily volume of 37,865 shares, the days-to-cover ratio is presently 0.7 days.

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded shares of Pluri from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, August 26th. One analyst has rated the stock with a Sell rating, According to MarketBeat, Pluri has an average rating of “Sell”.

Pluri Trading Down 5.3%

Shares of NASDAQ:PLUR traded down $0.06 during midday trading on Thursday, reaching $1.08. The company had a trading volume of 41,594 shares, compared to its average volume of 17,418. Pluri has a 52-week low of $1.06 and a 52-week high of $4.87. The company’s 50 day moving average price is $1.59 and its 200 day moving average price is $2.45. The stock has a market cap of $13.34 million, a P/E ratio of -0.44 and a beta of 0.68.

Pluri (NASDAQ:PLUR) last issued its quarterly earnings results on Thursday, September 10th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.66) by $0.12. The company had revenue of $0.34 million for the quarter, compared to analysts’ expectations of $0.66 million.

About Pluri

Pluri (NASDAQ:PLUR) is a clinical-stage biotechnology company focused on the development and manufacturing of placental-derived cell therapy products. The company’s proprietary three-dimensional microcarrier expansion platform enables large-scale, off-the-shelf production of PLX (placental expanded) cells, which are being investigated for a range of acute and chronic conditions. Pluri’s approach seeks to combine the regenerative and immunomodulatory properties of stromal cells with a scalable manufacturing process that does not require patient-specific cell harvesting.

Pluri advances its pipeline through internally funded research programs and strategic collaborations with academic institutions and government agencies.